Evaxion Biotech (EVAX) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Evaxion Biotech has unveiled promising preclinical results for its cytomegalovirus vaccine program, EVX-V1, utilizing its AI-Immunology platform to trigger targeted immune responses. The innovative approach, which combines AI-identified antigens with a proprietary prefusion glycoprotein B antigen, marks a significant step towards developing an effective CMV vaccine. This development could potentially tap into the growing CMV treatment market, valued at $474.6 million in 2023, and poised for further growth.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
